Skip to main content

 

Submissions

Allergy & Anaphylaxis Australia (A&AA) is a charitable, non-profit organisation established in 1993 to support and assist those affected by allergy and anaphylaxis. A&AA is dedicated to assisting individuals, their caregivers and all in the community in the management of allergic conditions including food allergy. A&AA’s aim is to enable individuals and their families to enjoy an optimal quality of life whilst minimising risk to their health and wellbeing. A&AA strives to raise awareness of allergy in the community and provides evidence-based information, resources and services to support children and adults living with allergic disease including food allergy. 

Select a link below to access A&AA's submission.

Submission to change to PBS listing of MEPOLIZUMAB Nucala® for uncontrolled severe asthma 30/01/2024

Please find below the joint submission from Allergy & Anaphylaxis Australia (A&AA) and the National Allergy Council to the Pharmaceutical Benefits Advisory Committee (PBAC) on changes requested by GlaxoSmithKline Australia Pty Ltd to the Pharmaceutical Benefits Scheme listing of mepolizumab (Nucala®) for uncontrolled severe asthma. We support the requested...

Continue reading

Submission to the PBAC on PBS listing of Neocate® Syneo - Amino acid formula supplemented with prebiotics, probiotics and long chain polyunsaturated fatty acids 29/01/2024

AMINO ACID FORMULA SUPPLEMENTED WITH PREBIOTICS, PROBIOTICS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS - Neocate® Syneo: Cows' milk protein enteropathy; Severe cows' milk protein enteropathy with failure to thrive; Combined intolerance to cows' milk protein, soy protein and protein hydrolysate formulae; Proven combined immunoglobulin E (IgE) mediated allergy to...

Continue reading

Submission to PBAC on PBS listing of LEBRIKIZUMAB (EBGLYSS®) for severe atopic dermatitis (eczema) 29/01/2024

Please find below the joint submission from Allergy & Anaphylaxis Australia (A&AA) and the National Allergy Council to the Pharmaceutical Benefits Advisory Committee (PBAC) on the Pharmaceutical Benefits Scheme listing of Lebrikizumab (Ebglyss®) for the treatment of patients aged 12 years or older with severe atopic dermatitis (AD), affecting the whole...

Continue reading

Submission to PBAC on PBS listing of Dupilumab (Dupixent®) for severe uncontrolled asthma 29/01/2024

The National Allergy Council and Allergy & Anaphylaxis Australia (A&AA) both support the submission from Sanofi-Aventis to request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) Pharmaceutical Benefits Scheme (PBS) listing of dupilumab (Dupixent®) for the treatment of uncontrolled severe asthma in patients aged 6 to 11 years. The...

Continue reading

Australian medicine labelling rules – Targeted consultation on priorities for future improvements to TGO 91 and TGO 92 - 7 September 2023

Do we need to update more medicine labelling rules in the short term to support medicine safety before we conduct a broader review? Yes, Allergy & Anaphylaxis Australia (A&AA) believes that an update is required in the short term to the ‘’Declaration of Substances’’, with respect to the food allergens that must be declared. It is vital that information...

Continue reading

PROPOSED DRAFT REVISION OF THE GENERAL STANDARD FOR THE LABELLING OF PRE-PACKAGED FOODS (CXS 1-1985) 4 September 2023

PROVISIONS RELEVANT TO ALLERGEN LABELLING (FOR ADOPTION AT STEP 5)  Allergy & Anaphylaxis Australia (A&AA) does not support the proposed Draft Revision on the General Standard for the Labelling of Pre-Packaged Foods (CXS 1-1985): Provisions relevant to Allergen Labelling for adoption at Step 5. A&AA has several concerns that we needed to...

Continue reading

PROPOSED DRAFT GUIDELINES ON THE PROVISION OF FOOD INFORMATION FOR PRE-PACKAGED FOODS - 4 September 2023

OFFERED VIA E-COMMERCE (FOR ADOPTION AT STEP 5) Allergy & Anaphylaxis Australia (A&AA) supports the proposed Draft Guidelines on the Provision of Food Information for Prepackaged foods offered via E-Commerce for adoption at Step 5. A&AA has one point that we believe needs to be considered. The definition of ‘consumer’, referred to in the Purpose...

Continue reading

PROPOSED DRAFT GUIDELINES ON THE USE OF TECHNOLOGY TO PROVIDE FOOD INFORMATION - 4 September 2023 (2)

IN FOOD LABELLING (FOR ADOPTION AT STEP 5)  Allergy & Anaphylaxis Australia (A&AA) supports the proposed Draft Guidelines on the Use of Technology to provide Food Information in Food Labelling for adoption at Step 5. However, we did have two issues that we feel need to be considered: The definition of consumer. In the Purpose statement...

Continue reading

P1028 – Infant formula | Special Medical Purpose Products for Infants (SMPPi) 7 July 2023

A&AA (Allergy & Anaphylaxis Australia) supports the proposal by FSANZ (Food Standards Australia New Zealand) to create a new category of infant formula that has been developed for a specific disease, disorder, or medical condition within Standard 2.9.1. A&AA supports the proposed sale restriction of a SMPPi (Special Medical Purpose Products for Infants)....

Continue reading

Ongoing PBS listing of Dupilumab for treatment of chronic severe atopic dermatitis - 15 May 2023

This submission from Allergy & Anaphylaxis Australia (A&AA) to the Pharmaceutical Benefits Advisory Committee concerns the ongoing Pharmaceutical Benefits Scheme listing of Dupilumab (Dupixent®) for the treatment of chronic severe atopic dermatitis in people aged 12 years and over. A&AA is grateful for the opportunity to forward a submission expressing...

Continue reading

Submission concerning Jorveza® for EoE change to current PBS listing - 23 Jan 2023

Submission from Allergy & Anaphylaxis Australia (A&AA): We welcome the opportunity to lodge our comments in support of the submission for Jorveza® (Budesonide) which is on the March 2023 Pharmaceutical Benefits Advisory Committee (PBAC) meeting agenda. Jorveza® was PBS listed in May 2022 specifically for the treatment of EoE. This application is for...

Continue reading

Submission on change to PBS listing Mepolizumab Injection - 15 Sep 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Change to PBS listing Mepolizumab Injection (Nucala®) to include use for people diagnosed with chronic rhinosinusitis with nasal polyps. A&AA supports the PBS listing of Mepolizumab so that people with chronic rhinosinusitis with nasal polyps can, together with their treating medical...

Continue reading

Submission concerning Codex Committee on Food Labelling | Response - 8 July 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Codex Committee on Food Labelling | Electronic Working Group on Allergen Labelling.  A&AA provides response on 1st Consultation Paper on the Codex eWG Allergen Labelling online-forum. Response form A&AA to Codex Committee on Food Labelling 8 July 2022195.71 KB    ...

Continue reading

Submission concerning Codex Contact Point - 7 July 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Codex Contact Point for Australia Secretariat A&AA appreciates the opportunity to provide feedback to the Codex Contact Point for Australia Secretariat on food information requirements for pre-packaged foods offered via e-commerce. Submission concerning Codex Contact Point - 7 July 2022224.86...

Continue reading

FSANZ submission: P1028 - Infant formula -14 June 2022

Allergy & Anaphylaxis Australia lodged a further submission with Food Standards Australia New Zealand (FSANZ) with regard to P1028 - Infant formula. A&AA supports the creation of a new category Special Medical Purpose Products for infants (SMPPi) within Standard 2.9.1, and supports the proposed labelling requirements for inner packages, preferably...

Continue reading

Submission concerning Dupixent for severe eczema - 16 May 2022

Submission from Allergy & Anaphylaxis Australia (A&AA):Dupixent for severe eczema.  A&AA asks that you consider the changed lives of people with severe eczema who are now taking Dupixent in the July 2022 PBAC meeting. People are utilising the medication because there has been a huge need for a treatment that works without the need for immunosuppressive...

Continue reading

Submission concerning Review of the WA Food Act - 3 May 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Review of the WA Food Act.  A&AA has no issue with the efficacy of the current provisions in the WA Food Act, noting that they appear in line with the Model Food Provisions. A&AA strongly urges the addition of provisions in the WA Food Act to address food allergy management throughout...

Continue reading

Submission concerning Food allergen content exemptions - 30 April 2022

Submission from Allergy & Anaphylaxis Australia (A&AA): Food allergen content exemptions cannot be considered because there is a huge food safety risk to consumers with food allergy. This will impact greatly on the health and wellbeing of people with food allergy and potentially add more of a challenge to an existing crisis such as Covid-19/natural disasters....

Continue reading

Submission concerning Proposal P1053: Food safety management tools - 6 April 2022

Allergy & Anaphylaxis Australia lodged a submission with Food Standards Australia New Zealand Food Standards Australia New Zealand (FSANZ) concerning Proposal P1053: Food safety management tools for the food service and closely related retail sectors. Submission from Allergy & Anaphylaxis Australia: Proposal P1053: Food safety management tools231.59...

Continue reading

Submission on draft Guidelines on the Use of Technology to Provide Food Information - 25 February 2022

Allergy & Anaphylaxis Australia lodged a submission with Codex Australia concerning the proposed Guidelines on the Use of Technology to Provide Food Information. A&AA Submission on draft Guidelines on the Use of Technology to Provide Food Information - 25 February 2022332.58 KB  

Continue reading

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.